4//SEC Filing
Sperzel John J III 4
Accession 0000899243-23-007724
CIK 0001492674other
Filed
Mar 8, 7:00 PM ET
Accepted
Mar 9, 4:00 PM ET
Size
14.2 KB
Accession
0000899243-23-007724
Insider Transaction Report
Form 4
Sperzel John J III
DirectorSee Remarks
Transactions
- Exercise/Conversion
Common Stock
2023-02-24+6,667→ 20,227 total - Sale
Common Stock
2023-02-28$0.59/sh−2,898$1,710→ 17,329 total - Exercise/Conversion
Common Stock
2023-02-20+16,000→ 20,435 total - Sale
Common Stock
2023-02-22$0.65/sh−6,875$4,469→ 13,560 total - Exercise/Conversion
Restricted Stock Units
2023-02-20−16,000→ 32,000 total→ Common Stock (16,000 underlying) - Exercise/Conversion
Restricted Stock Units
2023-02-20−6,667→ 6,667 total→ Common Stock (6,667 underlying)
Footnotes (4)
- [F1]Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- [F2]The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person adopted by the reporting person on May 20, 2021.
- [F3]On February 20, 2022 the reporting person was granted 48,000 RSU's that vest in three equal annual installments commencing on February 20, 2023
- [F4]On February 24, 2021 the reporting person was granted 20,000 RSU's that vest in three equal annual installments commencing on February 24, 2022.
Documents
Issuer
T2 Biosystems, Inc.
CIK 0001492674
Entity typeother
Related Parties
1- filerCIK 0001602618
Filing Metadata
- Form type
- 4
- Filed
- Mar 8, 7:00 PM ET
- Accepted
- Mar 9, 4:00 PM ET
- Size
- 14.2 KB